retatrutide phase 2 trial obesity nejm 2023 results Retatrutide (not yet approved in US but people using anyway) promises even potentially greater weight loss amongst the GLP1 drugs. https://www.nejm .org/doi/full/10.1056/NEJMoa2301972 Retatrutide Vial — Lyophilized, HPLC

These medications are another reminder that obesity is a complex chronic disease influenced by biology, genetics, medications, sleep, stress, food environments, and social factors

In another photo, Schumer was photo-bombed by her and husband Chris Fischer 's son, Gene David

By understanding how melanin works and how methods compare, consumers can focus on safety as they go for their look

First as secondary endpoints, then as trials explicitly designed for kidney disease: CREDENCE (Perkovic et al, NEJM 2019 | NephJC Summary), DAPA-CKD (Heerspink et al, NEJM 2020 | NephJC Summary), and EMPA-KIDNEY (Herrington et al, NEJM 2022 | NephJC Summary), each progressively widening eligibility